Skip to main content
Premium Trial:

Request an Annual Quote

Partek, Gene Logic Partner on Integrated Gene Analysis Software for GeneExpress

Premium

Partek has added its Partek Pro 2000 statistical and visual analysis software to a growing list of software tools to be integrated with Gene Logic’s software platform for its GeneExpress suite of databases.

“One of our key drivers is assessing our constituency’s use of software — what does the pharma and biotech industry use to analyze data in house,” said Robert Burrows, director ofcorporate communications at Gene Logic.

GeneLogic has also formed similar partnerships with Spotfire and Silicon Genetics.

There are no financial stipulations in the integration partnership, which is based solely on a mutual decision to integrate the companies’ software, Burrows said.

The integration will allow users of the GeneExpress suite to export gene or sample attributes, together with gene expression data, to Partek Pro 2000 for analysis. Users can then save the analyzed gene or sample sets into the GeneExpress workspace and use these results for further analysis.

Partek Pro 2000 uses a statistics-based approach for gene expression data analysis. DJ Meyer, vice president of Partek, said that gene expression analysis is “not viewed as a statistics problem now, but it certainly will be in the future.”

Meyer said that over 40 sites are currently using Partek’s software. The company’s pharmaceutical and biotech customers include Affymax, Akkadix, Boehringer Ingelheim, Merck, Novartis, Incyte Genomics, and Millennium Pharmaceuticals.

Of the Gene Logic partnership, Meyer said, “They have data, we have analysis tools. It made a lot of sense to have the conduit between the two software products go smoothly.”

Meyer said that Partek’s software is easily integrated with other sources through a built-in connect module. Due to this connectivity ability, the Gene Logic integration project only took a couple of months to complete.

Partek expects to announce other integration projects shortly.

— BT

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.